PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22700809-4	2012	RESULTS: Prior to IFN-beta treatment, each 10 nmol/L increase in 25-hydroxyvitamin D was associated with 12.7% (p = 0.037) reduced odds for new T1 gadolinium-enhancing lesions, 11.7% (p = 0.044) for new T2 lesions, and 14.1% (p = 0.024) for combined unique activity.	25-hydroxyvitamin D	65-84	interferon beta 1	Homo sapiens	18-26	
29243005-1	2018	BACKGROUND: Low serum levels of 25-hydroxyvitamin D have been associated with worse outcomes in multiple sclerosis (MS) patients treated with interferon-beta.	25-hydroxyvitamin D	32-51	interferon beta 1	Homo sapiens	142-157	
25312909-1	2015	OBJECTIVE: To investigate whether those genes involved in the vitamin D pathway modulate the relationship between 25-hydroxyvitamin D (25(OH)D) and IFN-beta, the relationship between IFN-beta and sun in predicting 25(OH)D, and the interaction between IFN-beta and 25(OH)D in modulating relapse risk in patients with MS. METHODS: Prospective cohort study of 169 participants with MS and genotype data followed 2002-2005.	25-hydroxyvitamin D	114-133	interferon beta 1	Homo sapiens	148-156	
26037530-6	2016	The association between IFN-beta treatment and 25-hydroxyvitamin D was similar in patients carrying any of the two alleles in the WT1 SNPs (rs10767935 and rs5030244) recently reported to modulate this relationship.	25-hydroxyvitamin D	47-66	interferon beta 1	Homo sapiens	24-32